MRK vs V: Which Is the Better Buy?
Side-by-side comparison of Merck & Co., Inc. and Visa Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-05-20.
Merck & Co., Inc. · Healthcare
$114.27
+3.3% upside to fair value
Grade C
High Quality
VS
Visa Inc. · Financial Services
$304.36
+45.0% upside to fair value
High Conviction
Grade A-
QuantHub Verdict
V has more upside to fair value
(+45.0%).
MRK trades at a lower forward P/E
(22.4x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
MRK |
V |
| Current Price |
$114.27 |
$304.36 |
| Fair Value Estimate |
$118.00 |
$441.32 |
| Upside to Fair Value |
+3.3%
|
+45.0%
|
| Market Cap |
$282.2B |
$586.8B |
| Forward P/E |
22.4x
|
23.7x
|
| EV / EBITDA |
13.5x
|
22.3x
|
| Price / Sales |
4.3x
|
14.2x
|
| Price / FCF |
20.2x
|
25.6x
|
| Revenue Growth YoY |
+5.0%
|
+11.3%
|
| Gross Margin |
81.9%
|
81.08%
|
| Operating Margin |
27.5%
|
59.18%
|
| Return on Equity |
5.6%
|
54.22%
|
| Dividend Yield |
2.91% |
0.83% |
| FCF Yield |
4.95%
|
3.91%
|
| Analyst Consensus |
Overweight
|
Strong Buy
|
Investment Thesis
Merck delivered a clean Q1 2026 operational beat on April 30, with revenue of 16.3 billion dollars growing 5 percent year over year and Keytruda sales rising 12 percent to 8.0 billion dollars. The reported loss of 1.28 dollars per share, though better than the negative 1.47 dollar consensus estimate, reflected a 3.62 dollar per share IPR and D charge tied to the Cidara Therapeutics acquisition an…
Visa is the world's dominant payment network with $40B in net revenue (FY2025), 50%+ net margins, and a capital-light toll-booth model processing $14.2T in annual payment volume across 257.5B transactions. The business compounds at 10-12% revenue CAGR with operating leverage pushing EPS growth to 12-15% over a cycle, funded by $21.6B in annual free cash flow against only $1.5B in capex. At 28.0x …
Accumulation Zones
| Metric |
MRK |
V |
| Zone Low |
$88.50 |
$330.99 |
| Zone High |
$100.30 |
$375.12 |
| In Buy Zone? |
No
|
Yes
|